ストックスクリーナーアプリを入手
0.014
7.89%
-0.0012
アフターアワーズ：
.01
-0.004
-28.57%
前日終値:
$0.0152
開ける：
$0.0152
24時間の取引高:
23,246
Relative Volume:
0.38
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-37.78%
1か月 パフォーマンス:
+102.90%
6か月 パフォーマンス:
+150.00%
1年 パフォーマンス:
-63.25%
1日の値動き範囲:
$0.014
$0.0152
1週間の範囲:
$0.014
$0.0237
52週間の値動き範囲:
$0.0009
$0.0698
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
NLSPW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.014 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ag (NLSPW) 最新ニュース
NLS Pharmaceutics CEO Issues Letter to Shareholders - marketscreener.com
NLS Pharmaceutics Announces June 2025 Shareholders’ Meeting Amid Financial Losses - TipRanks
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia
NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com India
NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Seeking Alpha
NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World
Narcolepsy Therapeutics Market Expected to Reach USD 7,852.93 Million by 2034, Growing at a CAGR of 7.5% As... - WhaTech
Narcolepsy Market: Epidemiology, Therapies, Companies, - openPR.com
Pre-market Movers: STSS, THRD, PTN, VRAX... - RTTNews
Press Release Distribution & PR Platform - ACCESS Newswire
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com
NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks
Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener
NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - marketscreener.com
Kadimastem Ltd. announced that it expects to receive ILS 2 million in funding. - marketscreener.com
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
Nls Pharmaceutics Ag (NLSPW) 財務データ
Nls Pharmaceutics Ag (NLSPW) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):